ImageneBio, Inc. Operating Cash Flow
ImageneBio, Inc. (IMA) reported Operating Cash Flow of -$23.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- ImageneBio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$9.07M.
- ImageneBio, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$14.80M.
- ImageneBio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.22M.
- ImageneBio, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$21.50M, a 265.83% decline year-over-year.
- ImageneBio, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$47.84M.
- ImageneBio, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$21.32M.
- ImageneBio, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$79.74M.
- ImageneBio, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$74.11M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$23.87M 10-Q · filed 2026-08-05 | -$31.09M derived: sum of 3 quarters · filed 2026-08-05 | -$52.59M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$14.80M 10-Q · filed 2026-05-07 | -$22.02M derived: sum of 2 quarters · filed 2026-05-07 | -$43.51M derived: sum of 3 quarters · filed 2026-05-07 | -$55.41M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$28.71M derived: sum of 2 quarters · filed 2026-03-10 | -$40.61M derived: sum of 3 quarters · filed 2026-08-05 | -$47.84M 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | -$21.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$33.40M derived: sum of 2 quarters · filed 2026-08-05 | -$40.63M 10-Q · filed 2025-11-12 | -$44.10M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$11.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$19.13M 10-Q · filed 2026-08-05 | -$13.98M 10-Q · filed 2025-07-24 | -$22.61M derived: sum of 3 quarters · filed 2026-08-05 | -$9.64M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | -$7.23M 10-Q · filed 2026-05-07 | -$10.56M 10-Q · filed 2025-05-08 | -$10.71M derived: sum of 2 quarters · filed 2026-05-07 | $2.26M derived: sum of 3 quarters · filed 2026-05-07 | -$10.24M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $9.49M derived: sum of 2 quarters · filed 2026-03-10 | -$3.02M derived: sum of 3 quarters · filed 2026-03-10 | -$21.32M 10-K · filed 2026-03-10 | -$46.00M 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $12.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $460.00K derived: sum of 2 quarters · filed 2025-11-12 | -$17.84M 10-Q · filed 2025-11-12 | -$39.74M 10-Q · filed 2024-11-07 | -$39.66M derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | -$12.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-24 | -$30.81M 10-Q · filed 2025-07-24 | -$52.63M derived: sum of 3 quarters · filed 2025-07-24 | -$72.62M derived: sum of 4 quarters · filed 2025-07-24 | ||||
| 2024-03-31 | -$18.30M 10-Q · filed 2025-05-08 | -$40.12M derived: sum of 2 quarters · filed 2025-05-08 | -$60.12M derived: sum of 3 quarters · filed 2025-05-08 | -$78.26M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$21.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$41.82M derived: sum of 2 quarters · filed 2025-03-06 | -$59.96M derived: sum of 3 quarters · filed 2025-03-06 | -$79.74M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | -$20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$38.14M derived: sum of 2 quarters · filed 2024-11-07 | -$57.92M 10-Q · filed 2024-11-07 | -$75.58M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$18.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$37.93M 10-Q · filed 2024-08-08 | -$55.58M derived: sum of 3 quarters · filed 2024-08-08 | -$72.80M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$19.78M 10-Q · filed 2024-05-13 | -$37.44M derived: sum of 2 quarters · filed 2024-05-13 | -$54.66M derived: sum of 3 quarters · filed 2024-05-13 | -$74.11M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | -$17.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$34.87M derived: sum of 2 quarters · filed 2024-03-12 | -$54.33M derived: sum of 3 quarters · filed 2024-03-12 | -$74.11M 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | -$17.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$36.67M derived: sum of 2 quarters · filed 2023-11-09 | -$56.45M 10-Q · filed 2023-11-09 | -$69.82M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | -$19.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$39.23M 10-Q · filed 2023-08-10 | -$52.60M derived: sum of 3 quarters · filed 2023-08-10 | -$70.59M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$19.78M 10-Q · filed 2023-05-15 | -$33.15M derived: sum of 2 quarters · filed 2023-05-15 | -$51.14M derived: sum of 3 quarters · filed 2023-05-15 | -$66.87M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$13.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$31.36M derived: sum of 2 quarters · filed 2023-03-14 | -$47.08M derived: sum of 3 quarters · filed 2023-03-14 | -$60.25M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | -$17.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$33.71M derived: sum of 2 quarters · filed 2022-11-07 | -$46.88M 10-Q · filed 2022-11-07 | -$59.45M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | -$15.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$28.89M 10-Q · filed 2022-08-11 | -$41.46M derived: sum of 3 quarters · filed 2022-08-11 | -$49.13M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$13.17M 10-Q · filed 2022-05-12 | -$25.74M derived: sum of 2 quarters · filed 2022-05-12 | -$33.41M derived: sum of 3 quarters · filed 2022-05-12 | -$41.12M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$12.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$20.24M derived: sum of 2 quarters · filed 2022-03-17 | -$27.95M derived: sum of 3 quarters · filed 2022-03-17 | -$37.83M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | -$7.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$15.38M derived: sum of 2 quarters · filed 2021-11-10 | -$25.26M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | -$7.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$17.59M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$9.87M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |